Paraneoplastic Thrombocytosis in Ovarian Cancer

Paraneoplastic thrombocytosis in ovarian cancer.

BACKGROUND The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear. METHODS We analyzed clinical data on 619 patients with epithelial ovarian cancer to test associations between platelet counts and disease outcome. Human samples and mouse models of epithelial ovarian cancer were used to explore the underlying mec...

Paraneoplastic thrombocytosis in breast cancer.

BACKGROUND Elevated platelet count at the time of diagnosis has been suggested to identify a subset of patients with cancer (e.g. ovarian and lung adenocarcinoma) and poor prognosis. The evidence on the incidence and prognostic significance of thrombocytosis in breast cancer is, however, incomplete. PATIENTS AND METHODS We performed a retrospective analysis of 127 consecutive patients with br...

Role of interleukin-6 in paraneoplastic thrombocytosis.

Paraneoplastic cerebellar degeneration associated with ovarian cancer

Paraneoplastic cerebellar degeneration (PCD) is a rare neurological disorder characterized by a widespread loss of Purkinje cells associated with a progressive pancerebellar dysfunction. PCD often precedes the cancer diagnosis by months to years. Here, we report the case of a 64-year-old woman who developed PCD symptoms, associated with high levels of anti-Yo antibodies, one year after a previo...

Androgen mediation of thrombocytosis in epithelial ovarian cancer biology.

PURPOSE Preoperative thrombocytosis (platelet count > 400 x 10(9)/L) at initial exploration for epithelial ovarian carcinoma is associated with decreased surgical cytoreducibility and poor survival. Platelets express androgen receptor (AR), which contains a polymorphic CAG trinucleotide repeat sequence of which the length inversely correlates with AR transactivation function. We hypothesized th...